D58.1 Hereditary elliptocytosis

Name of the Condition

• Hereditary elliptocytosis

Summary

Hereditary elliptocytosis is an inherited disorder characterized by the production of abnormally shaped red blood cells (elliptocytes) that are prone to premature destruction (hemolysis). This leads to chronic hemolytic anemia, jaundice, and an enlarged spleen. The condition results from defects in red blood cell membrane proteins, which disrupt the cell's structural integrity and cause it to lose its normal biconcave shape.

Causes

Hereditary elliptocytosis is caused by inherited genetic mutations that affect proteins in the red blood cell membrane, such as spectrin, ankyrin, or band 3. These mutations impair the cell's ability to maintain its shape, leading to the formation of elliptical cells that are less flexible and more likely to be destroyed in the spleen. The condition is typically inherited in an autosomal dominant pattern, though autosomal recessive forms exist.

Risk Factors

• Family history of hereditary elliptocytosis
• Inherited genetic mutations in red blood cell membrane proteins
• Ethnic background (more common in individuals of African, Mediterranean, or Southeast Asian descent)
• Triggers that exacerbate hemolysis (e.g., infections, certain medications, oxidative stress)

Symptoms

• Fatigue and weakness due to anemia
• Jaundice (yellowing of skin or eyes) from increased bilirubin
• Pale skin or mucous membranes
• Enlarged spleen (splenomegaly)
• Dark urine (hemoglobinuria) in severe cases

Diagnosis

Diagnosis typically involves a blood smear to identify elliptocytes, followed by confirmatory tests such as osmotic fragility testing or flow cytometry. Genetic testing may be used to identify specific mutations. Additional evaluations, including a complete blood count (CBC) and reticulocyte count, assess anemia severity and red blood cell production.

Treatment Options

Treatment focuses on managing symptoms and complications. Mild cases may not require intervention. For moderate to severe anemia, options include folic acid supplementation to support red blood cell production, blood transfusions during acute hemolysis, and splenectomy (surgical removal of the spleen) in refractory cases. Avoidance of triggers like oxidative stress is also recommended.

Prognosis and Follow-Up

Prognosis varies depending on the severity of the condition. Mild forms may have minimal impact on daily life, while severe cases can lead to chronic anemia and complications. Regular follow-up with a hematologist is recommended to monitor anemia, spleen size, and overall health. Long-term management may involve periodic blood tests and imaging studies.

Complications

• Chronic hemolytic anemia
• Gallstones (due to increased bilirubin)
• Splenomegaly with potential for splenic rupture
• Iron deficiency from chronic blood loss
• Increased risk of infections (post-splenectomy)

Lifestyle & Prevention

• Avoid known triggers of hemolysis (e.g., certain medications, infections)
• Maintain a balanced diet rich in folic acid
• Stay hydrated to support overall health
• Monitor for signs of anemia or jaundice
• Seek prompt medical care for infections or illness

When to Seek Professional Help

• Persistent fatigue, weakness, or jaundice
• Unexplained dark urine or pale skin
• Abdominal pain or fullness (possible splenomegaly)
• Signs of infection (fever, chills)
• Sudden worsening of symptoms or new complications

Tips for Medical Coders

When coding for hereditary elliptocytosis (D58.1), ensure documentation supports the diagnosis, including clinical findings (e.g., elliptocytes on blood smear) and genetic testing results if available. Verify that the condition is not secondary to another disorder. Accurate coding requires specifying the exact type of hereditary elliptocytosis if documented, as subtypes may exist. Review clinical notes for details on severity, treatment, or complications to ensure complete coding.